Amgen (NASDAQ: AMGN) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE